We have also successfully demonstrated the potential of the combination therapy of platinum agents and CHD4 inhibitor by introducing the first-in-class SMARCA5/CHD4 inhibitor ED2-AD101 in ovarian cancer cells. Here, SMARCA5 is linked to ovarian carcinoma.